New combo therapy aims to shrink ovarian tumors before surgery
NCT ID NCT05739981
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better reduce cancer before surgery in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assigned to receive either the standard treatment or the standard treatment plus IMNN-001. The goal is to see if the new combination leads to less cancer remaining at the time of a second-look surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Medicine SKCCC
COMPLETEDBaltimore, Maryland, 21231, United States
-
Memorial Sloan Kettering Cancer Center
ACTIVE_NOT_RECRUITINGNew York, New York, 10065, United States
-
OU Health, Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••
Contact
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.